• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens
【24h】

Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens

机译：评论和回复：培格非司亭在预防嗜中性白血球减少症和每两周一次的治疗延迟方面是安全有效的

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pegfilgrastim is regarded today as the standard therapy in the primary prophylaxis of febrile neutropenia induced by three-weekly chemotherapy regimens while its use with biweekly regimens is still controversial. Pegfilgrastim clearance is mainly mediated by binding to granulocyte colony stimulating factor (G-CSF) receptors found on myeloid bone marrow elements and neutrophils and the recovery of neutrophils count to levels in excess of 1.000/ml is associated with subtherapeutic levels of pegfilgrastim. Silvestris et al. confirmed diat a single dose of pegfilgrastim in appropriate patients provides a more convenient and effective strategy for assisting neutrophil recovery. Given these data, the authors designed a prospective study in which they administered one dose of pegfilgrastim (6 mg s.c. 48 h after treatment completion) to 20 consecutively enrolled patients affected by colorectal cancer (13), pancreas cancer (2), biliary tract cancer (2) and other type of cancers (3), who developed at least a grade 3 neutropenia during a biweekly regimen despite receiving filgrastim 30/0.6, 1 s.c. for 5 days. The study design was approved by internal ethical committee. Patients received Folfiri (7), Folfox (6), Folfoxiri (2) or other biweekly regimens (4). The basal value of white blood cells (WBCs) and polymorphonuclear leukocytes (PMNs) was recorded at days 14 and 28 as well as the incidence of treatment delays.
机译：如今，培格非司亭被认为是三周化疗方案诱导的发热性中性粒细胞减少症的一级预防的标准疗法，但与双周方案联合使用仍存在争议。 pegfilgrastim清除主要是通过与髓样骨髓元素和中性粒细胞上发现的粒细胞集落刺激因子（G-CSF）受体结合而介导的，中性粒细胞的恢复至超过1.000 / ml的水平与pegfilgrastim亚治疗水平相关。 Silvestris等。确认适当剂量的患者接受单剂量的pegfilgrastim治疗可帮助中性粒细胞恢复提供更便捷有效的策略。鉴于这些数据，作者设计了一项前瞻性研究，在该研究中，他们向20例连续受结肠直肠癌（13），胰腺癌（2），胆道癌影响的患者服用了一个剂量的吡非司亭（6 mg sc在治疗后48小时）。 （2）和其他类型的癌症（3），尽管接受非格司亭30 / 0.6、1 sc的治疗，但每两周一次至少发生3级中性粒细胞减少5天。研究设计得到内部伦理委员会的批准。患者接受了Folfiri（7），Folfox（6），Folfoxiri（2）或其他每两周一次的治疗方案（4）。在第14和28天记录白细胞（WBC）和多形核白细胞（PMN）的基础值以及治疗延迟的发生率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号